Trials / Active Not Recruiting
Active Not RecruitingNCT05320692
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 423 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TACE+Camrelizumab+Apatinib mesylate | TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks. |
| PROCEDURE | TACE | TACE Alone. |
Timeline
- Start date
- 2022-08-09
- Primary completion
- 2026-07-30
- Completion
- 2026-07-30
- First posted
- 2022-04-11
- Last updated
- 2025-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05320692. Inclusion in this directory is not an endorsement.